In vitro diagnostic substrate sales will expand through 2036, with alkaline phosphatase substrate holding 29.6% of the substrate type segment in 2026, driven by established clinical adoption and treatment protocol integration. The market was valued at USD 1.80 billion in 2025 and is expected to be worth USD 3.64 billion by 2036.